A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3021-3021 ◽  
Author(s):  
V. Moreno Garcia ◽  
R. D. Baird ◽  
K. J. Shah ◽  
B. Basu ◽  
N. Tunariu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors ◽  
Phosphoinositide 3 Kinase

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3005-3005 ◽  
Author(s):  
H. Burris ◽  
J. Rodon ◽  
S. Sharma ◽  
R. S. Herbst ◽  
J. Tabernero ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3035-3035 ◽  
Author(s):  
A. Patnaik ◽  
L. J. Appleman ◽  
J. M. Mountz ◽  
R. K. Ramanathan ◽  
M. Beeram ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

scholarly journals Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors

2019 ◽  
Vol 110 (3) ◽  
pp. 1021-1031 ◽  
Author(s):  
Yuichi Ando ◽  
Satoru Iwasa ◽  
Shunji Takahashi ◽  
Hideo Saka ◽  
Tomoyuki Kakizume ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Japanese Patients ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2541-2541 ◽  
Author(s):  
D. D. Von Hoff ◽  
P. LoRusso ◽  
R. Tibes ◽  
G. Shapiro ◽  
G. J. Weiss ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3003-3003 ◽  
Author(s):  
J. Baselga ◽  
M. J. De Jonge ◽  
J. Rodon ◽  
H. A. Burris ◽  
D. C. Birle ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document